Skip to main content
. Author manuscript; available in PMC: 2020 Jan 17.
Published in final edited form as: ACS Omega. 2019 Dec 24;5(1):822–831. doi: 10.1021/acsomega.9b03626

Figure 2.

Figure 2

An optimised soluble analogue, compound 9, is active in FP (A) and ITC (B) assays. (C) Activity of the isolated enantiomers of compound 9 in the FP assay. For FP assays values are the mean of three independent experiments ±SD. A representative experiment is shown for ITC. The experiment was carried out in duplicate.